| Literature DB >> 36068613 |
Zhenpeng Zhu1,2,3, Jiayu Yang4, Yudong Zheng5, Jian Lin6,7,8, Liqun Zhou9,10,11, Xing Ji1,2,3, Zicheng Wang12, Chengxiang Dai4,13, Suke Li13, Xuesong Li1,2,3, Yajie Xie4.
Abstract
BACKGROUND: Urethral stricture and reconstruction are one of the thorny difficult problems in the field of urology. The continuous development of tissue engineering and biomaterials has given new therapeutic thinking to this problem. Bacterial cellulose (BC) is an excellent biomaterial due to its accessibility and strong plasticity. Moreover, adipose-derived stem cells (ADSCs) could enhance their wound healing ability through directional modification.Entities:
Keywords: Adipose-derived stem cell; Angiogenesis; Bacterial cellulose; Sulfonated; Urethral reconstruction
Mesh:
Substances:
Year: 2022 PMID: 36068613 PMCID: PMC9450280 DOI: 10.1186/s13287-022-03164-9
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 8.079
Fig. 1Flowchart of the whole experimental processes
Fig. 2A Microstructure of BC, MBC, SBC, and SMBC; B surface scan images of BC, MBC, SBC, and SMBC
Fig. 3A Stress − strain curves, B tensile strength, and C elongation at break of BC, MBC, SBC, and SMBC; D biocompatibility of BC, MBC, SBC, and SMBC, “ns”: no significance; E, F Contact angles of BC, MBC, SBC, and SMBC; (g) GFP fluorescence of BC, MBC, SBC, SMBC; the scale bar is 100 μm
Fig. 4A ADSCs cells under white light and fluorescence; B, C Partial size of protein and mRNA expression levels of overexpressed FGFR2; D, E proliferation, migration and invasion ability of FGFR2 ctrl and OE ADSCs; F Osteogenic and adipogenic differentiation capacity of FGFR2 ctrl and OE ADSCs. “**”, < 0.01; “***”, < 0.001
Fig. 5A Differential gene heatmap between two groups; B KEGG enrichment analyses of the differential genes; C GSEA enrichment analyses of the two groups
Fig. 6A Differential cytokines dot plot between two groups; B Elisa analyses of the VEGFA between two groups; C Proliferation ability of HuVECs in different cell supernatants treated; D Angiogenic capacity of HuVECs under co-culture conditions (×200). E Angiogenic capacity of HuVECs under co-culture conditions and Bevacizumab (500 nM) (×200). F Proliferation ability of HuVECs in different cell supernatants treated and Bevacizumab (500 nM)
Fig. 7A, B Urography and urethroscopy of Negative controls, FGFR2 ctrl and FGFR2 OE groups at 1 month and 3 months after surgery; C VEGFA; D HE; E MASSON; F Prussian blue; G AE1/AE3; H CD31; I CD34; J alpha-SMA; K Desmin of Negative controls, FGFR2 ctrl and FGFR2 OE groups at 1 month and 3 months after surgery
Detailed follow-ups of rabbits between different groups
| Negative controls | FGFR2 Ctrl | FGFR2 OE | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| State at the end point | Alive | Alive | Alive | Alive | Dead | Alive | Alive | Alive | Alive | Alive | Alive | Dead | Alive | Alive | Alive | Alive | Alive | Alive |
| Endpoint | 1 month | 1 month | 1 month | 3 month | 3 month | 3 month | 1 month | 1 month | 1 month | 3 month | 3 month | 3 month | 1 month | 1 month | 1 month | 3 month | 3 month | 3 month |
| Grossly: | ||||||||||||||||||
| + | − | + | + + + | + + + | + | + + | + | + + | − | − | + + + | − | + | − | + | − | − | |
| − | − | − | + | − | + | − | − | − | − | − | + | − | − | − | − | − | − | |
| Histology | ||||||||||||||||||
| + | + | + | + + | + | + + | + + | + | + + | + + | + + | + | + + + | + + + | + + | + + + | + + + | + + + | |
| + + | + | + | + + | + + | + + | + + | + | + + | + + | + + | + | + + | + + + | + + | + + + | + + + | + + | |
| + + + | + + | + | + | + + + | + | + | + | + + + | + | − | + + | − | + | − | − | − | + | |
| + | + | + + | + | + | + | + | + + | + | + + | + | + + | + + | − | + + | + + + | + + | + + | |
| Other complications | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
0–3 + , "−" Negative; "+" Weak; "++" Moderate; "+++" Strong